Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?
Willemien Beukers(Erasmus University Rotterdam), Geert J.L.H. van Leenders(Erasmus MC Cancer Institute), Ellen C. Zwarthoff(Erasmus MC), C. J. Vissers(Meertens Institute), Titia G. Meijer(Erasmus MC), Joost L. Boormans(Erasmus MC)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
July 10, 2012
Cited by 9
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|381